Renal Cell Carcinoma Perspective

 
 
  • Renal Cell Carcinoma Highlights From ESMO 2020   Dr Robert Motzer reviews key studies on renal cell carcinoma presented at the 2020 ESMO Virtual Congress, including phase 3 trial results showing benefit from combination therapies in advanced RCC.
  • ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
  • AUA 2020 Read clinically focused news coverage of key developments from AUA 2020
  • Will Coronavirus Restrictions Lead to More Advanced Cancers? The coronavirus epidemic will almost certainly shed new light on restricted medical procedures like cancer screening going forward.
  • GUCS 2020 Read clinically focused news coverage of key developments from GUCS 2020
  • Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade Lung cancer experts Jack West and Charu Aggarwal highlight the biggest immunotherapy trials in thoracic oncology from 2010 to 2019.
  • Fecal Transplants: 5 Things to Know Research continues to expand regarding potential uses of fecal microbiota transplantation, but safety concerns are growing following a patient's death. Here are the latest data you need to know.
  • Renal Cell Carcinoma: 5 Things to Know What you need to know about the latest data on treating this common cancer.
  • Setbacks and Advances in Renal Cell Carcinoma Treatment Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.
  • Checkpoint Inhibitors: Powerful Drugs With Severe Side Effects Would you recognize a cutaneous adverse effect of these powerful agents? A new study can help -- and provides key information about management.
  • AUA 2019 Read clinically focused news coverage of key developments from AUA 2019
  • 'Immuno-Revolution' Has Oncologists 'Forgetting About Chemo' Chemotherapy still plays a major role in oncology, even in diseases revolutionized by immunotherapy; however, oncologists are becoming less and less familiar with prescribing it, argues Ravi Parikh.
  • EAU 2019 Read clinically focused news coverage of key developments from EAU 2019
  • GUCS 2019 Read clinically focused news coverage of key developments from GUCS 2019.
  • Interpreting the 'Messy Early Days' of Immunotherapy in Breast Cancer Peter Schmid, the 'Most Popular Man in San Antonio,' discusses the long-awaited results of IMpassion130, the ground-breaking trial evaluating immunotherapy for metastatic triple-negative breast cancer.
  • Top News From ESMO 2018: Slideshow Practice changing data on prostate cancer, new hope in triple negative breast cancer and the potential for chemo-free head and neck cancer therapy featured prominently this year.
  • Hard Lessons From Year 1 of Oncology Fellowship Loss of autonomy. Practicing in areas of medicine without good evidence. Providing end-of-life care. Oncology fellowship comes with its own unique set of tough lessons.
  • Oncologists' Off-Label Prescribing Pits Access Against Reimbursement Off-label prescribing in oncology is undergoing a change: Payers are more restrictive in their reimbursement for off-label uses, while oncologists are keen to provide access to new immunotherapies.
  • Medscape Physicians' Choice: Top Hospitals for Cancer Treatment Medscape surveyed more than 11,000 physicians to get their opinions on which hospitals they'd send family members to in order to have serious and complex cancer cases treated.
  • Kris: 'Don't Be Afraid to Use the Word "Cure" When It's Possible'   Can we reimagine cancer treatment to cure patients? Dr Mark Kris discusses this major theme from ASCO 2018.